NCT00577278 2024-02-16
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
Phase 2 Completed
Clinical Trials
15 trialsNCT00290511 2022-04-22
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00637832 2022-01-06
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
Phase 2 Terminated
NCT01493479 2019-10-15
FIZZ
The Christie NHS Foundation Trust
Phase 2 Completed
NCT00732498 2019-09-04
ESHAP
University of Arizona
Phase 2 Completed
NCT00695409 2018-07-06
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT00119392 2018-06-29
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00110149 2017-11-21
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Terminated
NCT01446562 2016-06-17
ZEVISS
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT00310128 2016-02-03
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Phase 2 Withdrawn
NCT00005592 2015-10-21
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Alabama at Birmingham
Phase 2 Completed
NCT01130194 2014-05-12
MasterPlan
St. Louis University
Phase 2 Completed
NCT00772655 2012-08-02
Zevalin® First Line in Follicular Lymphoma
Charite University, Berlin, Germany
Phase 2 Unknown
NCT00859001 2009-03-12
FM+R-Z
University of Bologna
Phase 2 Completed
NCT00722930 2008-07-28
GOTEL-FL1LC
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Phase 2 Unknown